Skip to main content
OpenTrials

Clinical trial condition

Hepatitis

Explore clinical trials studying Hepatitis. Study availability and eligibility vary by location and protocol.

2,967 public trials 189 recruiting studies
Refine in advanced search Browse all conditions

Hepatitis trial results

Completed

Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-naïve Genotype 1 Hepatitis C Infected Patients (STARTverso 1)

NCT01343888

Conditions
Blood-Borne Infections, Communicable Diseases, Digestive System Diseases, +8 more
Locations
  • 1220.30.4303 Boehringer Ingelheim Investigational Site Linz, Austria
  • 1220.30.4301 Boehringer Ingelheim Investigational Site Vienna, Austria
  • 1220.30.4302 Boehringer Ingelheim Investigational Site Vienna, Austria
  • 1220.30.4304 Boehringer Ingelheim Investigational Site Vienna, Austria
View all 98 locations
View Trial Details
Completed

UNITY 3: A Japanese Phase 3 Study of a Daclatasvir/Asunaprevir/BMS-791325 in Subjects With Genotype 1 Chronic Hepatitis C

NCT02123654

Conditions
Blood-Borne Infections, Communicable Diseases, Digestive System Diseases, +9 more
Locations
  • Local Institution Nagoya, Aichi-ken, Japan
  • Local Institution Nagoya, Aichi-ken, Japan
  • Local Institution Fukui-shi, Fukui, Japan
  • Local Institution Fukuoka, Japan
View all 35 locations
View Trial Details
Completed

Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-naïve Genotype 1 Hepatitis C Infected Patients (STARTverso 2)

NCT01297270

Conditions
Blood-Borne Infections, Communicable Diseases, Digestive System Diseases, +8 more
Locations
  • 1220.47.0004 Boehringer Ingelheim Investigational Site Birmingham, Alabama, United States
  • 1220.47.0045 Boehringer Ingelheim Investigational Site Birmingham, Alabama, United States
  • 1220.47.0050 Boehringer Ingelheim Investigational Site Dothan, Alabama, United States
  • 1220.47.0061 Boehringer Ingelheim Investigational Site Phoenix, Arizona, United States
View all 106 locations
View Trial Details
Completed

Safety and Efficacy of Daclatasvir (BMS-790052) Plus Standard of Care in Japanese Patients (Pegylated-interferon Alpha-2a and Ribavirin)

NCT01017575

Conditions
Blood-Borne Infections, Communicable Diseases, Digestive System Diseases, +9 more
Locations
  • Local Institution Chiba, Japan
  • Local Institution Kurume-Shi, Fukuoka, Japan
  • Local Institution Okayama, Okayama-ken, Japan
  • Local Institution Osaka, Japan
View Trial Details
Completed

Short Term Treatment With BI 201335, Peginterferon-alpha 2a and Ribavirin in Hepatitis c Virus Genotype-1 Treatment-naïve Patients (SILEN-C3)

NCT00984620

Conditions
Blood-Borne Infections, Communicable Diseases, Digestive System Diseases, +8 more
Locations
  • 1220.40.002 Boehringer Ingelheim Investigational Site Tulepo, Mississippi, United States
  • 1220.40.007 Boehringer Ingelheim Investigational Site New York, United States
  • 1220.40.006 Boehringer Ingelheim Investigational Site Germantown, Tennessee, United States
  • 1220.40.004 Boehringer Ingelheim Investigational Site Jackson, Tennessee, United States
View all 28 locations
View Trial Details
Completed

Comparison of Plasma & SMARTplasma for Human Immunodeficiency Virus (HIV) and Hepatitis C Virus (HCV) Antibody Testing

NCT01447680

Conditions
Acquired Immunodeficiency Syndrome, Blood-Borne Infections, Communicable Diseases, +20 more
Locations
  • Therafirst Medical Centers Fort Lauderdale, Florida, United States
  • American Red Cross Douglasville, Georgia, United States
  • Evelyn Jordan Center Baltimore, Maryland, United States
  • University of Maryland, School of Medicine Baltimore, Maryland, United States
View Trial Details

Related conditions